ストックスクリーナーアプリを入手
1.92
3.23%
0.06
アフターアワーズ：
1.95
0.03
+1.56%
前日終値:
$1.86
開ける：
$1.86
24時間の取引高:
591.35K
Relative Volume:
0.85
時価総額：
$241.39M
収益：
-
当期純損益:
$-35.47M
株価収益率:
-3.5861
EPS:
-0.5354
ネットキャッシュフロー:
$-124.27M
1週間 パフォーマンス:
-12.53%
1か月 パフォーマンス:
-20.00%
6か月 パフォーマンス:
+17.07%
1年 パフォーマンス:
-58.08%
1日の値動き範囲:
$1.86
$1.9998
1週間の範囲:
$1.80
$2.29
52週間の値動き範囲:
$1.12
$4.85
Prokidney Corp Stock (PROK) Company Profile
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-21 | 開始されました | Jefferies | Buy |
| 2022-11-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-10-18 | 開始されました | UBS | Buy |
| 2022-10-14 | 開始されました | Citigroup | Buy |
| 2022-09-23 | 開始されました | BofA Securities | Buy |
| 2022-09-02 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Prokidney Corp (PROK) 最新ニュース
Recent Insider Activity Suggests Potential Gains for ProKidney Corp (PROK) - Knox Daily
ProKidney (NASDAQ:PROK) Coverage Initiated by Analysts at JPMorgan Chase & Co. - MarketBeat
An In-Depth Look at ProKidney Corp Inc. (PROK) Price Performance During Market Crashes - The InvestChronicle
ProKidney Corp (PROK)’s Day in Review: Closing at 1.86, Down by -8.82 - The Dwinnex
JPMorgan starts ProKidney stock coverage with Neutral rating - Investing.com
How does ProKidney Corp (PROK) change from a tortoise to a hare? - SETE News
Insider Selling: Weber Darin J., ProKidney Corp [PROK] Chief Regulatory Officer divested 16,412 shares - Knox Daily
Insiders Re-Evaluate Their US$54.7m Stock Purchase As ProKidney Falls To US$659m - Simply Wall St
ProKidney Corp (PROK) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Is it possible to buy ProKidney Corp(PROK) shares at a good price now? - US Post News
Examining the Potential Price Growth of ProKidney Corp (PROK) - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing ProKidney Corp (PROK)’s Performance - The Dwinnex
ProKidney revises Phase 3 program for lead asset - MSN
Reviewing LadRx (OTCMKTS:CYTR) and ProKidney (NASDAQ:PROK) - Defense World
ProKidney (NASDAQ:PROK) Sees Unusually-High Trading Volume - Defense World
ProKidney Corp. (NASDAQ:PROK) Insider Darin J. Weber Sells 16,412 Shares - MarketBeat
ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com South Africa
ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com Australia
ProKidney executive sells $41,030 in company stock - Investing.com India
ProKidney executive sells $41,030 in company stock - Investing.com
ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com UK
ProKidney (NASDAQ:PROK) Shares Down 6.7% - MarketBeat
Propel Hits 52-Week High on KOHO Link - Baystreet.ca
Propel Holdings Inc. - Baystreet.ca
Wall Street Analyst Initiated ProKidney Corp [PROK]. What else is Wall St. saying - The DBT News
ProKidney Corp [PROK] stock for 2,065 USD was sold by Weber Darin J. - Knox Daily
ProKidney (NASDAQ:PROK) Sees Strong Trading Volume - MarketBeat
PROK’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Stocks to Watch: Steelcase, Progyny, America's Car-Mart, Exicure - MarketWatch
ProKidney Corp (PROK) stock analysis: A simple moving average approach - US Post News
Potential Price Increase for ProKidney Corp (PROK) After Recent Insider Activity - Knox Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: ProKidney Corp (PROK) - SETE News
Financial Metrics Exploration: Understanding ProKidney Corp (PROK) Through Ratios - The Dwinnex
ProKidney (NASDAQ:PROK) Shares Gap Down to $2.38 - MarketBeat
ProKidney - The Pharma Letter
ProKidney (NASDAQ:PROK) Shares Down 3.3% - MarketBeat
ProKidney (NASDAQ:PROK) Now Covered by Analysts at Guggenheim - Defense World
Investing in ProKidney Corp (PROK) Is Getting More Attractive - Knox Daily
ProKidney (NASDAQ:PROK) Shares Gap Up to $2.39 - MarketBeat
ProKidney (NASDAQ:PROK) Earns Buy Rating from Analysts at Guggenheim - MarketBeat
Guggenheim highlights ProKidney stock upside in addressing unmet needs for CKD patients - Investing.com Canada
Guggenheim Initiates Coverage of ProKidney (PROK) with Buy Recommendation - Nasdaq
Guggenheim highlights ProKidney stock upside in addressing unmet needs for CKD patients - Investing.com
ProKidney updates on rilparencel’s registrational path to potential US approval - The Pharma Letter
ProKidney (NASDAQ:PROK) Trading 6% Higher - MarketBeat
ProKidney Suspends One of Its Two Phase 3 Kidney Cell Therapy Trials - DocWire News
ProKidney (NASDAQ:PROK) Price Target Lowered to $3.00 at Bank of America - Defense World
ProKidney (NASDAQ:PROK) Shares Gap Down on Analyst Downgrade - Defense World
ProKidney drops Phase III CKD study to focus on US market and save up to $175m - Clinical Trials Arena
BofA cuts ProKidney shares target as cash shortfall raises risksBofA - Investing.com
ProKidney drops Phase III CKD study to focus on US market and save up to $175m - Yahoo Finance
Prokidney Corp (PROK) 財務データ
収益
当期純利益
現金流量
EPS
0.05%
4.86%
大文字化:
|
ボリューム (24 時間):